Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
fda
2
×
life sciences
national blog main
alprazolam
amgen
billy dunn
biogen
boston blog main
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
drug enforcement administration
drug prices
drug pricing
eli lilly
europe top stories
evrysdi
gene therapy
genentech
indiana
indiana blog main
indiana top stories
ionis pharmaceuticals
lasmiditan
migraine research foundation
national
national top stories
new york top stories
novartis
nusinersen
raleigh-durham blog main
raleigh-durham top stories
risdiplam
rna drugs
roche
san francisco top stories
spinal muscular atrophy
spinraza
What
drug
fda
friday
2
×
new
2
×
acute
addresses
approval
approved
atrophy
causes
condition
daily
decades
eli
evrysdi
giant
giving
green
home
intended
lasmiditan
lights
lilly
lilly’s
liquid
medication
medicine
migraine
muscular
oks
oral
patients
pharmaceutical
risdiplam
roche
second
spinal
therapy
won
Language
unset
Current search:
friday
×
fda
×
new
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
